Personalized treatment with PARP inhibitors in advanced urothelial carcinoma: a case report and literature review.

ABSTRACT: Bladder cancer (BC) poses a significant health challenge, particularly in metastatic cases, where the prognosis is unfavorable and therapeutic options are limited. Poly ADP-ribose polymerase (PARP) inhibitors have gained approval for use in various cancer types, but their application in BC remains controversial, despite the notable prevalence of DNA damage response alterations in advanced or metastatic urothelial carcinomas. In this report, we describe a 66-year-old heavy-smoking female diagnosed with muscle-invasive BC. She underwent multiple rounds of chemotherapy and radiation, yet her disease remained poorly controlled, leading to metastasis in the left obturator internus muscle. Comprehensive genomic profiling through FoundationOne^® Liquid CDx, examining a 324-gene panel us

SUBMITTER: Abbas N 

PROVIDER: S-EPMC11025443 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature